Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Not Confirmed
Not Confirmed
22-24 April, 2025
Not Confirmed
Not Confirmed
22-25 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Industry Trade Show
Not Confirmed
22-24 April, 2025
Industry Trade Show
Not Confirmed
22-25 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
Details:
The funding will support Passkey’s development of SMThs, a new class of single-drug therapies designed to modulate rare combinations of proteins that work together.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Undisclosed
Sponsor: Breakout Ventures
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 22, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Breakout Ventures
Deal Size : $20.0 million
Deal Type : Financing
Passkey Therapeutics Raises $20M for Multifunctional Therapeutics Platform
Details : The funding will support Passkey’s development of SMThs, a new class of single-drug therapies designed to modulate rare combinations of proteins that work together.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 22, 2024
ABOUT THIS PAGE